Pharmaceutical company Tris Pharma Inc revealed on Tuesday the completion of the acquisition of NextWave Pharmaceuticals, a wholly owned subsidiary of Pfizer Inc, including two key Attention Deficit Hyperactivity Disorder (ADHD) treatments, for an undisclosed amount.
ADHD is one of the most common neurodevelopmental disorders characterized by an ongoing pattern of inattention and/or hyperactivity and impulsivity.
Following closing, the acquisition further expands Tris' portfolio of products for the treatment of patients with ADHD.
This acquisition includes Quillivant XR, the first and only marketed extended-release oral liquid methylphenidate as well as QuilliChew ER, the first and only extended-release methylphenidate chewable tablet, both of which are central nervous system (CNS) stimulants approved for the treatment of ADHD.
In addition, Quillivant XR and QuilliChew ER were co-developed by NextWave and Tris, utilizing Tris' novel, proprietary LiquiXR platform.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference